PATH Stock: Buy or Sell? Price Target & Forecast

PATH UiPath Inc As of Jul 24, 2026

$10.20

RPA software leader trading 49% below 52-week high; growth deceleration vs. profitability expansion raises valuation tension.

Setup: Recovery / Value Inflection Confidence: 62 Horizon: 3-6 months Risk: medium Category: Growth / SaaS

🔒 Trade Plan — entry · target · stop

Entry Zone

$•••–•••

Target

$•••

Stop Loss

$•••

Risk / Reward

•.• : 1

Unlock the exact levels — free →

A free account reveals PATH's entry zone, price target & stop loss. Full 1-week to 1-year price forecasts are included with Pro.

The Thesis

▲ Bull Case

Net margin 17.5% (profitable SaaS); 15% YoY revenue growth + 21.5% 5Y CAGR; P/E 16x below historical; net cash likely (2.48x current ratio); P/FCF 15x reasonable for automation TAM; insider buying signal (12 buys vs 122 sells may indicate floor-seeking).

▼ Bear Case

Revenue growth deceleration (15% YoY vs 21.5% 5Y); P/S 3.3x / EV/EBITDA 81x suggest premium persists despite slowdown; insider selling dominance (122 vs 12 buys, 43M vs 29M shares) signals confidence erosion; -47% from 52W high indicates sentiment collapse; growth-to-value rotation headwind.

Valuation

Mixed — Profitability attractive, growth deceleration concerning, multiple elevated but compressed from highs. — score 58/100

P/E 16.1x is fair for SaaS with 17.5% net margin + 15% revenue growth, but multiples (P/S 3.3x, EV/EBITDA 81x, P/FCF 15x) suggest market still prices in higher growth trajectory than current 15% YoY. Valuation reset underway; fair value likely 12–14 range if growth stabilizes.

Technical Levels

Support · $9.20 (52W low) · $9.80 (Recent low (3–4 weeks)) · $10.16 (Today's intraday low)

Resistance · $10.96 (Today's intraday high) · $11.50 (Intermediate resistance) · $14.00 (200-day MA / trend support (est.)) · $19.84 (52W high)

RSI: Not provided

Financial Health

Score 81/100. Fortress balance sheet. 2.48x current ratio and 2.42x quick ratio indicate ample cash to fund operations, R&D, and potential downturns. Minimal intangible asset bloat (tangible BV ~$3.84 vs book $3.88). No solvency red flags. Debt level unknown but structure suggests low leverage.

Catalysts

Next earnings report (estimated 1–2 months)	Q1/Q2 2025 (TBD)	High — Revenue guidance, margin trajectory, and management commentary on AI/automation demand will reset investor expectations. Beat could trigger 15–20% rebound; miss or conservative guide could break down to 8–9 range.
AI automation narrative / competitive positioning	Ongoing	Medium — Partnership announcements with major cloud (Azure) or enterprise platforms could re-rate upside; conversely, commoditization news (Microsoft native RPA) could pressure multiple.
Insider activity reversal	Next 2–4 weeks	Medium — If buy/sell ratio flips toward buys, signals management confidence and could stabilize stock in 11–12 range. Sustained selling below 10 is bearish.
Macro / SaaS tape	Ongoing	Medium — Recession or SaaS spending pullback could drag entire sector down; conversely, enterprise digital transformation acceleration helps PATH.

Risk Flags

Insider selling far exceeds buying (122:12 ratio, 43M vs 29M shares); sentiment erosion signal despite potential valuation appeal.

Revenue growth deceleration from 21.5% 5Y to 15% YoY; sustainability of high margins unconfirmed amid slowing top line.

EV/EBITDA 81x and P/S 3.3x remain elevated; earnings quality and growth trajectory clarity needed before multiple re-rates.

RSI, fundamentals depth (income statement, balance sheet, cash flow detail), and debt-to-equity unavailable; liquidity/solvency assessment incomplete.

Recent news theme: stock dip as 'buying opportunity' but also 'Why?' questions; analyst sentiment not provided. Data stale risk if market has moved.

See PATH's full trade plan — free

Create a free account to unlock the exact entry, target, and stop — plus run live analysis on any of 5,000+ tickers. No card required.

Unlock PATH free →

More Analyses

TEAM

NVDA

AAPL

TSLA

MSFT

AMZN

PATH FAQ

Is PATH a buy right now?

UiPath Inc's current read is a Recovery / Value Inflection setup with 62 confidence over a 3-6 months horizon. Valuation: Mixed — Profitability attractive, growth deceleration concerning, multiple elevated but compressed from highs.. See the full bull and bear case above, or run a live analysis for the exact entry, target and stop.

Is PATH overvalued?

Mixed — Profitability attractive, growth deceleration concerning, multiple elevated but compressed from highs. (valuation score 58/100). P/E 16.1x is fair for SaaS with 17.5% net margin + 15% revenue growth, but multiples (P/S 3.3x, EV/EBITDA 81x, P/FCF 15x) suggest market still prices in higher growth trajectory than current 15% YoY. Valuation reset underway; fair value likely 12–14 range if growth stabilizes.

What are the risks of buying PATH?